<DOC>
	<DOCNO>NCT01011010</DOCNO>
	<brief_summary>RATIONALE : Sorafenib tosylate may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , doxorubicin hydrochloride mitomycin , work different way stop growth tumor cell , either kill cell stop dividing . Chemoembolization kill tumor cell carry drug directly tumor block blood flow tumor . Giving sorafenib tosylate together chemoembolization may kill tumor cell . PURPOSE : This phase I trial study side effect sorafenib tosylate give together chemoembolization doxorubicin hydrochloride mitomycin treat patient liver cancer remove surgery .</brief_summary>
	<brief_title>Sorafenib Tosylate Chemoembolization With Doxorubicin Hydrochloride Mitomycin Treating Patients With Liver Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine safety sorafenib tosylate give combination transarterial chemoembolization ( TACE ) comprise doxorubicin hydrochloride mitomycin C patient unresectable hepatocellular carcinoma . Secondary - To estimate time progression ( TTP ) patient treat regimen . - To estimate overall survival ( OS ) patient treat regimen . - To explore correlative relationship measure serum VEGF peri-procedure TACE period change TACE sorafenib tosylate well patient outcome ( TTP OS ) . OUTLINE : This multicenter study . Patients receive oral sorafenib tosylate twice daily day 1-14 . Patients undergo transarterial chemoembolization ( TACE ) comprise doxorubicin hydrochloride mitomycin C day 17-19* . Patients receive oral sorafenib tosylate twice daily begin recovery TACE continue absence disease progression unacceptable toxicity . NOTE : *A second course TACE may administer within 8 week first TACE procedure . Blood sample may collect periodically biomarker pharmacokinetic analysis . After completion study treatment , patient follow 3-4 week every 3 month 3 year .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis hepatocellular carcinoma ( HCC ) , define 1 following : Tissue histology Recurrence previously resect HCC require tissue confirmation clear radiographic recurrence , judgment investigator AFP &gt; 400 ng/mL compatible mass MRI Locally advance disease Not eligible surgical resection immediate liver transplantation OR refuse procedure All disease must amenable embolization one two procedure Measurable disease , accord modify HCC RECIST criterion Must radiographically document measurable disease least one site disease unidimensionally measurable ≥ 10 mm MRI Lesions previously treat radiofrequency ablation represent site measurable disease ChildsPugh score ≤ 7 No complete thrombosis main portal vein If unilateral portal vein thrombosis present , must demonstrate radiographic evidence adequate flow lobe embolized No evidence extrahepatic/metastatic disease , lymph node metastasis , lung bone metastasis , peritoneal carcinomatosis Evidence cirrhosis acceptable long lab parameter meet No know brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy ≥ 12 week Hemoglobin ≥ 9.0 g/dL ANC ≥ 1,500/mm³ Platelet count ≥ 75,000/mm³ Creatinine ≤ 1.5 time upper limit normal ( ULN ) OR creatinine clearance ≥ 50 mL/min Total bilirubin ≤ 3 mg/dL ALT AST ≤ 5 time ULN INR &lt; 1.5 Negative pregnancy test Fertile patient must use effective contraception ≥ 3 month completion study treatment No cancer within past 3 year except cervical carcinoma situ , previously treat basal cell carcinoma , superficial bladder tumor ( Ta , Tis , T1 ) No NYHA class III IV congestive heart failure No unstable angina ( anginal symptom rest ) newonset angina within past 3 month No myocardial infarction within past 6 month No cardiac ventricular arrhythmia require antiarrhythmic therapy No uncontrolled hypertension ( i.e. , systolic BP &gt; 150 mm Hg diastolic BP &gt; 90 mm Hg , despite optimal medical management ) No venous thrombotic arterial embolic event ( e.g. , cerebrovascular accident , include transient ischemic attack venous thromboembolism ) within past 6 month No pulmonary hemorrhage/bleeding event &gt; CTCAE grade 2 within past 12 week No hemorrhage/bleeding event &gt; CTCAE grade 3 within past 12 week No variceal bleed within past 12 week No know grade 2 3 esophageal varix ( endoscopic evaluation require study entry ) No evidence history bleed diathesis coagulopathy No significant traumatic injury within past 12 week No serious nonhealing wound , ulcer , bone fracture No significant proteinuria ( i.e. , proteinuria &gt; 1+ urine dipstick ) No HIV positivity ( patient report ) No active hepatitis B C , unless patient stable medication ≥ 2 month No active clinically serious infection ( &gt; grade 2 ) No active gastrointestinal malabsorption problem No condition would impair patient 's ability swallow whole pill No active drug alcohol abuse No know severe hypersensitivity suspect allergy sorafenib tosylate , excipients , drug use study No psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule PRIOR CONCURRENT THERAPY : No prior systemic therapy , embolic therapy , radiotherapy HCC ( e.g. , chemotherapy , transarterial chemoembolization , transarterial embolization , 90Y microspheres ) At least 4 week since prior liver resection ablative therapy recover No prior Raf/MEK/ERKtargeted therapy VEGFtargeted therapy More 4 week since prior participation investigational drug study More 12 week since prior major surgery open biopsy Prior core liver biopsy allow No concurrent antiretroviral therapy HIV No concurrent chronic anticoagulation ( 1 mg warfarin daily port patency ) No concurrent St. John wort rifampin No concurrent anticancer therapy , radiotherapy , investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
</DOC>